{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T16:22:17Z","timestamp":1780762937324,"version":"3.54.1"},"reference-count":33,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,12,29]]},"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Psoriasis and psoriatic arthritis (PsA) are independently associated with comorbidities, including obesity and metabolic syndrome, which may impact treatment outcomes. This study aimed to assess baseline differences between patients with plaque psoriasis alone and those with concomitant PsA, and to investigate the impact of these characteristics on ustekinumab (UST) persistence and outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>9057 patients receiving UST or conventional systemic disease-modifying antirheumatic drugs were selected from the British Association of Dermatologists Biologic and Immunomodulators Register. The psoriasis and PsA cohorts were compared at baseline. Time to discontinuation during 10-year follow-up was assessed using multivariable Cox regression and Kaplan\u2013Meier analyses, stratifying for interacting covariates and PsA status. Generalised linear mixed models assessed the impact of baseline characteristics on Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index over time.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Greater comorbidity burden, including hypertension, diabetes, obesity and depression, and greater inability to work were observed in the PsA cohort than in the psoriasis cohort. PsA (HR 1.98), female sex (HR for male sex 0.72) and depression (HR 1.21) were associated with shorter UST persistence. PsA showed a differential association with UST persistence by PASI strata and prior biologic exposure. Quality of life was negatively impacted by depression and PsA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The negative impact of comorbidities on treatment persistence identified in this study emphasises the need for patient-centric, multidisciplinary care in screening for and managing comorbidities in psoriasis and PsA treatment. Psychological support and lifestyle management of modifiable risk factors, including obesity, should be considered.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002533","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T04:26:04Z","timestamp":1674015964000},"page":"e002533","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-4125","authenticated-orcid":false,"given":"William","family":"Tillett","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, UK"},{"name":"Department of Life Sciences, University of Bath, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alun","family":"Passey","sequence":"additional","affiliation":[{"name":"Janssen-Cilag Ltd, High Wycombe, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Gorecki","sequence":"additional","affiliation":[{"name":"Janssen-Cilag Ltd, High Wycombe, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,1,17]]},"reference":[{"key":"2025090313475904000_9.1.e002533.1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0191-y"},{"key":"2025090313475904000_9.1.e002533.2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex323"},{"key":"2025090313475904000_9.1.e002533.3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40744-018-0135-1","article-title":"Patient perspective on the burden of skin and joint symptoms of psoriatic arthritis: results of a multi-national patient survey","volume":"6","author":"Merola","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2025090313475904000_9.1.e002533.4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40744-020-00221-8","article-title":"Disease characteristics and the burden of joint and skin involvement amongst people with psoriatic arthritis: a population survey","volume":"7","author":"Tillett","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2025090313475904000_9.1.e002533.5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00296-020-04775-2","article-title":"Comorbidities in psoriatic arthritis: a systematic review and meta-analysis","volume":"41","author":"Gupta","year":"2021","journal-title":"Rheumatol Int"},{"key":"2025090313475904000_9.1.e002533.6","doi-asserted-by":"crossref","first-page":"737079","DOI":"10.3389\/fmed.2021.737079","article-title":"Extra-Articular manifestations and comorbidities in psoriatic disease: a journey into the immunologic crosstalk","volume":"8","author":"Novelli","year":"2021","journal-title":"Front Med"},{"key":"2025090313475904000_9.1.e002533.7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/acr.22926","article-title":"Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2025090313475904000_9.1.e002533.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190729"},{"key":"2025090313475904000_9.1.e002533.9","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/jdv.13611","article-title":"Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR)","volume":"30","author":"Menter","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025090313475904000_9.1.e002533.10","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.17738","article-title":"Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis","volume":"181","author":"Mourad","year":"2019","journal-title":"Br J Dermatol"},{"key":"2025090313475904000_9.1.e002533.11","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000181"},{"key":"2025090313475904000_9.1.e002533.12","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1007\/s10067-019-04663-6","article-title":"Psoriatic arthritis and obesity: the role of anti-IL-12\/IL-23 treatment","volume":"38","author":"Costa","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025090313475904000_9.1.e002533.13","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/bjd.18227","article-title":"Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis","volume":"182","author":"Green","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025090313475904000_9.1.e002533.14","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2217\/ijr.12.63","article-title":"Gender-Related differences in patients with psoriatic arthritis","volume":"7","author":"Eder","year":"2012","journal-title":"Int J Clin Rheumtol"},{"key":"2025090313475904000_9.1.e002533.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key140"},{"key":"2025090313475904000_9.1.e002533.16","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-1-65"},{"key":"2025090313475904000_9.1.e002533.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"2025090313475904000_9.1.e002533.18","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.3390\/jcm9103103","article-title":"Patient-Centered care in psoriatic arthritis-a perspective on inflammation, disease activity, and psychosocial factors","volume":"9","author":"Batko","year":"2020","journal-title":"J Clin Med"},{"key":"2025090313475904000_9.1.e002533.19","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/jamadermatol.2018.0183","article-title":"Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR","volume":"154","author":"Mason","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2025090313475904000_9.1.e002533.20","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000588"},{"key":"2025090313475904000_9.1.e002533.21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cpt.2474","article-title":"The role of real-world evidence in FDA-approved new drug and biologics license applications","volume":"111","author":"Purpura","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"2025090313475904000_9.1.e002533.22","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2133.2012.10835.x","article-title":"The British association of dermatologists' biologic interventions register (BADBIR): design, methodology and objectives","volume":"166","author":"Burden","year":"2012","journal-title":"Br J Dermatol"},{"key":"2025090313475904000_9.1.e002533.23","unstructured":"National Institute for Health and Care Excellence (NICE) . Psoriasis: assessment and management, CG153, 2012. Available: https:\/\/www.nice.org.uk\/guidance\/cg153\/chapter\/Introduction [Accessed May 2022]."},{"key":"2025090313475904000_9.1.e002533.24","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/bjd.18981","article-title":"Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)","volume":"183","author":"Yiu","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025090313475904000_9.1.e002533.25","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40744-021-00286-z","article-title":"Real-World treatment persistence with biologic disease-modifying antirheumatic drugs among German patients with psoriatic arthritis-a retrospective database study","volume":"8","author":"Sewerin","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2025090313475904000_9.1.e002533.26","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kws412"},{"key":"2025090313475904000_9.1.e002533.27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/09546634.2018.1479725","article-title":"Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity","volume":"30","author":"Murage","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"2025090313475904000_9.1.e002533.28","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2174\/1573397111666150619095330","article-title":"Psychosocial factors and central sensitivity syndromes","volume":"11","author":"Adams","year":"2015","journal-title":"Curr Rheumatol Rev"},{"key":"2025090313475904000_9.1.e002533.29","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/BOR.0000000000000388","article-title":"Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment","volume":"29","author":"Mease","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"2025090313475904000_9.1.e002533.30","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.2"},{"key":"2025090313475904000_9.1.e002533.31","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamadermatol.2018.1412","article-title":"Dietary recommendations for adults with psoriasis or psoriatic arthritis from the medical Board of the National Psoriasis Foundation: a systematic review","volume":"154","author":"Ford","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2025090313475904000_9.1.e002533.32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-019-1810-5","article-title":"Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study","volume":"21","author":"Klingberg","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025090313475904000_9.1.e002533.33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202812"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:48:12Z","timestamp":1756932492000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,17]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1136\/rmdopen-2022-002533"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002533","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}